Literature DB >> 3105867

Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines.

J H Schiller, G Bittner, B Storer, J K Willson.   

Abstract

We assessed the antiproliferative effects of tumor necrosis factor (TNF-alpha) and gamma-interferon (IFN-gamma) alone and in combination, on nine human colon carcinoma cell lines. All were resistant (less than 30% inhibition) to TNF-alpha alone. Four cell lines were resistant to IFN-gamma alone, two exhibited a minimal degree of sensitivity (30-50% inhibition), one was moderately sensitive, and two were inhibited 70% or greater. A synergistic antiproliferative effect occurred in eight of the nine cell lines treated with a combination of TNF-alpha and IFN-gamma. In seven of these eight, the combination of cytokines resulted in 30-40% more growth inhibition than predicted had an additive interaction occurred (P less than 0.005). In two cell lines with an induced resistance to mitomycin C, an increase in resistance to combined TNF-alpha and IFN-gamma treatment correlated with an increasing resistance to mitomycin C. The data were further analyzed to determine if combination treatment altered the sensitivity of the cells to one or both agents in addition to synergistically potentiating growth inhibitory effects. Combinations of TNF-alpha/IFN-gamma enhanced the dose response activity of TNF-alpha in three cell lines (P less than or equal to 0.09) and decreased the dose response activity of IFN-gamma in another three (P less than or equal to 0.02). Colony forming experiments on HCT 116 cells demonstrated a reduction in the number of 250-micron colonies in the IFN-gamma/TNF-alpha treatment groups when compared to controls, indicating that combined treatment had a cytotoxic effect. We conclude that combination TNF-alpha/IFN-gamma treatment has a synergistic cytotoxic effect on human colon carcinoma cells. IFN-gamma may enhance the effectiveness of TNF-alpha in some cell lines, but not conversely. These results may have therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105867

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha.

Authors:  L Mahraoui; M Heyman; O Plique; M T Droy-Lefaix; J F Desjeux
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

Authors:  J L Abbruzzese; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Posttranscriptional regulation of c-myc proto-oncogene expression and growth inhibition by recombinant human interferon-beta ser17 in a human colon carcinoma cell line.

Authors:  D Chatterjee; T M Savarese
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Interferon gamma and tumour necrosis factor alpha induce a synergistic antiproliferative response in human Ewing's sarcoma cells in vitro.

Authors:  F van Valen; W Winkelmann; S Burdach; U Göbel; H Jürgens
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.

Authors:  S H Murch; C P Braegger; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

6.  Anti-CD3/anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model.

Authors:  Isabelle Renard; Delia Mezzanzanica; Silvana Canevari; Silvano Ferrini; Jacques Boniver; Philippe Delvenne; Nathalie Jacobs
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

7.  Influence of intravesical administration of tumor necrosis factor alpha and systemic gamma-interferon on murine bladder cancer: lack of dose response.

Authors:  K Lee; R W O'Donnell; A T Cockett
Journal:  Urol Res       Date:  1990

8.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

9.  Chemosensitivity and cytokine sensitivity of malignant mesothelioma.

Authors:  R V Bowman; L S Manning; M R Davis; B W Robinson
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Fibroblast growth factor increases TNF alpha-mediated prostaglandin E2 production and TNF alpha receptor expression in human fibroblasts.

Authors:  M Candela; S C Barker; L R Ballou
Journal:  Mol Cell Biochem       Date:  1993-03-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.